Olema Pharmaceuticals Inc's Comment on Supply Chain
The company has a Clinical Trial Agreement with Pfizer, under which Pfizer supplies IBRANCE® (palbociclib) at no cost for clinical trials combining it with palazestrant. The company is responsible for manufacturing, packaging, and labeling palazestrant and other drugs used in the combined therapy trials, excluding IBRANCE®. Pfizer manufactures and delivers IBRANCE® in the quantities required for the clinical studies. The agreement includes termination provisions for conditions such as material breach, safety issues, or unresolved clinical holds. Pfizer is identified as a supplier in company filings.
Olema Pharmaceuticals Inc's Comment on Supply Chain
The company has a Clinical Trial Agreement with Pfizer, under which Pfizer supplies IBRANCE® (palbociclib) at no cost for clinical trials combining it with palazestrant. The company is responsible for manufacturing, packaging, and labeling palazestrant and other drugs used in the combined therapy trials, excluding IBRANCE®. Pfizer manufactures and delivers IBRANCE® in the quantities required for the clinical studies. The agreement includes termination provisions for conditions such as material breach, safety issues, or unresolved clinical holds. Pfizer is identified as a supplier in company filings.
Sources:
Olema Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Olema Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
